AIC
RVNC

Ameritas Investment Company’s Revance Therapeutics, Inc. RVNC Stock Holding History

Ameritas Investment Company’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-180
Closed -$3K – 1655
2020
Q1 		$3K Buy
+180
New +$3.72K ﹤0.01% 1524

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ameritas Investment Company's RVNC Position: Q2 2020 in Review

Ameritas Investment Company sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2020, closing a stake of 180 shares — an estimated $3K sold.

Ameritas Investment Company first reported a position in RVNC in Q1 2020 and held it in 1 quarter. The position peaked at $3K in Q1 2020. 144 funds tracked by Wall St. Rank hold RVNC as of Q2 2020.

  • Ameritas Investment Company reported no remaining Revance Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Ameritas Investment Company sold 180 Revance Therapeutics, Inc. shares in Q2 2020, an estimated $3K.
  • Ameritas Investment Company first reported a position in Revance Therapeutics, Inc. in Q1 2020 and held it in 1 quarter.
  • Ameritas Investment Company's Revance Therapeutics, Inc. position peaked at $3K in Q1 2020.
  • 144 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2020.

Based on Ameritas Investment Company's 13F filing for Q2 2020, filed 14 Aug 2020.